Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients

Inclusion Criteria: * 18\~65 years * Hepatitis virus C chronic infection evidences: HCV RNA or anti-HCV positive\>6 months,or other evidences supporting diagnosis of chronic hepatitis C infection * HCV RNA≥2000IU/mL, anti-HCV positive at screening * Pregnancy tests for female patients must be negative. All patients must take effective contraception measures during the study period * Signed informed consent Exclusion Criteria: * Pregnant or lactating women * Mental or psychology disorder * ANC\<1500/mm3, or PLT\<90,000/mm3, or Hb\<ULN(Upper limit of Normal) * Received interferon treatment within the previous 6 months or shown no-response to previous interferon treatment * Co-infection with HIV, HAV, HBV, HEV * Evidence of hepatic decompensation (e.g: Child Plug≥B, prothrombin time prolonged more than 3 seconds, TBil\>2ULN, Alb\<35g/L) * Hepatocarcinoma or suffering from any other malignant tumor * Not well controlled endocrine diseases(e.g:thyroid disfunction, mellitus mellitus) * Significant function damage in any major organs (e.g: heart, lung, kidney) * Involved in other investigation within the previous 3 months * Other conditions which in the opinion of the investigator precluding enrollment into the study (e.g: poor compliance)